The observation that inactivation of either E2F1 or E2F3 could significantly delay the onset of tumors and increase overall survival of osteosarcoma-bearing animals suggests that the increase malignancy upon Rb1 loss might be reversible, and that direct downstream targets of aE2Fs are valuable potential therapeutic targets. Here, RB1 is linked to osteosarcoma.